DS
ADMA icon

DRW Securities’s ADMA Biologics ADMA Stock Holding History

DRW Securities’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$121K Buy
+13,387
New +$211K ﹤0.01% 1178

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

DRW Securities's ADMA Position: Q1 2026 in Review

DRW Securities opened a new position in ADMA Biologics (ADMA) in Q1 2026: 13,387 shares worth $121K. The stake represents ﹤0.01% of the portfolio and ranks #1178 among its holdings.

356 funds tracked by Wall St. Rank hold ADMA as of Q1 2026.

  • DRW Securities held 13,387 shares of ADMA Biologics worth $121K as of Q1 2026.
  • ADMA Biologics was a new DRW Securities position in Q1 2026.
  • ADMA Biologics made up ﹤0.01% of DRW Securities's portfolio in Q1 2026, its #1178 holding.
  • 356 funds tracked by Wall St. Rank held ADMA Biologics as of Q1 2026.

Based on DRW Securities's 13F filing for Q1 2026, filed 13 May 2026.